Zerafa N, Westwood JA, Cretney E, Mitchell S, Waring P, Iezzi M, SmythMJ. Cutting edge: TRAIL deficiency accelerates hematologicalmalignancies. J Immunol 2005; 175:5586?90.

Zaki, M. H., K. L. Boyd, P. Vogel, M. B. Kastan, M. Lamkanfi, and T. D.Kanneganti. 2010. The NLRP3 inflammasome protects against loss ofepithelial integrity and mortality during experimental colitis. Immunity 32:379?391.

Yue HH, Diehl GE, Winoto A. Loss of TRAIL-R does not affect thymicor intestinal tumor development in p53 and adenomatous polyposis colimutant mice. Cell Death Differ 2005; 12:94?7.

Yu, K.Y. et al. Cutting edge: mouse pellino-2 modulates IL-1 andlipopolysaccharide signaling. J. Immunol. 169, 4075?4078 (2002).

Wu GS, Burns TF, Zhan Y, Alnemri ES, El-Deiry WS. Molecular cloningand functional analysis of the mouse homologue of the KILLER/DR5tumor necrosis factor-related apoptosis- inducing ligand (TRAIL) death96receptor. Cancer Res 1999; 59:2770?5.

Witz IP: Tumor-microenvironment interactions: dangerous liaisons. AdvCancer Res 2008, 100:203-229.

Wiley SR, Schooley K, Smolak PJ et al. Identification andcharacterization of a newmember of the TNF family that inducesapoptosis. Immunity 1995; 3:673?82.

Wei W, Wang D, Shi J, Xiang Y, Zhang Y, Liu S, Liu Y, Zheng D. Tumornecrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) induceschemotactic migration of monocytes via a death receptor 4-mediatedRhoGTPase pathway. Mol Immunol 2010; 47:2475?84.

Wang EL, Qian ZR, Nakasono M, Tanahashi T, Yoshimoto K, et al. (2010)High expression of Toll-like receptor 4/myeloid differentiation factor 88signals correlates with poor prognosis in colorectal cancer. Br J Cancer63102: 908?915.

Tsai WH1, Huang DY, Yu YH, Chen CY, Lin WW. Dual roles of NOD2 inTLR4-mediated signal transduction and -induced inflammatory geneexpression in macrophages. Cell Microbiol. 2011;13(5);717-30

Troisi RJ, Freedman AN, Devesa SS: Incidence of colorectal carcinoma inthe U.S.: an update of trends by gender, race, age, subsite, and stage,1975-1994. Cancer 1999, 85:1670-1676.

Tang W, Wang W, Zhang Y, Liu S, Liu Y, Zheng D. Tumour necrosisfactor-related apoptosis-inducing ligand (TRAIL)-induced chemokinerelease in both TRAIL-resistant and TRAIL-sensitive cells via nuclearfactor jB. FEBS J 2009; 276:581?93.

Somesh, B.P., Vlahou, G., Iijima, M., Insall, R.H., Devreotes, P., Rivero,F., 2006. RacG regulates morphology, phagocytosis, and chemotaxis.Eukaryot. Cell 5, 1648?1663.

Smyth, M. J., Takeda, K., Hayakawa, Y., Peschon, J. J., van den Brink, M.R., & Yagita, H. (2003). Nature ?s TRAIL?On a path to cancerimmunotherapy. Immunity, 18(1), 1?6.

Slattery ML, Herrick JS, Bondurant KL, Wolff RK (2011) Toll-likereceptor genes and their association with colon and rectal cancerdevelopment and prognosis. International journal of cancer Journalinternational du cancer.

Siednienko, J. et al. Pellino3 targets the IRF7 pathway and facilitatesautoregulation of TLR3- and viral-induced expression of type Iinterferons. Nat. Immunol. 13, 1055?1062 (2012).

Sica A, Bronte V: Altered macrophage differentiation and immunedysfunction in tumor development. J Clin Invest 2007, 117:1155-1166.

Shi J, Diao Z, Zhou J, Zhu J, Yuan H, You X, Liu Y, Zheng D. Epirubicinpotentiates recombinant adeno-associated virus type 2/5-mediated TRAILexpression in fibroblastlike synoviocytes and augments the antiarthriticeffects of rAAV2/5-TRAIL. Arthritis Rheum 2012; 64:1345?54.

Sekirov I, Russell SL, Antunes LCM, Finlay BB (2010) Gut Microbiotain Health and Disease. Physiological Reviews 90: 859?904.

Schauvliege, R., Janssens, S. & Beyaert, R. Pellino proteins: novelplayers in TLR and IL-1R signalling. J. Cell. Mol. Med. 11, 453?461(2007).

Schauvliege, R., Janssens, S. & Beyaert, R. Pellino proteins are more thanscaffold proteins in TLR/IL-1R signalling: a role as novel RING E3-ubiquitin-ligases. FEBS Lett. 580, 4697?4702 (2006).

Schaefer U, Voloshanenko O, Willen D, Walczak H. TRAIL: amultifunctional cytokine. Front Biosci 2007; 12:3813?24.

Paludan, S. R. & Bowie, A. G. Immune sensing of DNA. Immunity 38,870?880 (2013).

Ordureau, A. et al. The IRAK-catalysed activation of the E3 ligasefunction of Pellino

O ?Neill, L. A., Golenbock, D. & Bowie, A. G. The history of Toll-likereceptors ? redefining innate immunity. Nature Rev. Immunol. 13, 453?460 (2013).

Nathan, C.F., 1987. Neutrophil activation on biological surfaces. Massivesecretion of hydrogen peroxide in response to products of macrophagesand lymphocytes. J. Clin. Invest. 80, 1550?1560.

Munkholm, P. 2003. Review article: the incidence and prevalence ofcolorectal cancer in inflammatory bowel disease. Aliment. Pharmacol.Ther. 18(Suppl. 2):1?5.

Moynagh, P.N. Pellino3 ubiquitinates RIP2 and mediates Nod2-inducedsignaling and protective effects in colitis Nat. Immunol. 14, 927?936(2013).65

Moynagh, P.N. Pellino3 targets the IRF7 pathway and facilitatesautoregulation of TLR3- and viral-induced expression of type Iinterferons. Nat. Immunol. 11, 1055-1062 (2012).

Moynagh, P.N. Peli1 relieves autoimmunity. Nat. Immunol. 12, 927?929(2011).

Loo, Y. M. & Gale, M. Jr. Immune signaling by RIG-Ilike receptors.Immunity 34, 680?692 (2011).

LeBlanc, H. N., & Ashkenazi, A. (2003). Apo2L/TRAIL and its death anddecoy receptors. Cell Death Differ., 10(1), 66?75.

Kinzler KW, Vogelstein B: Lessons from hereditary colorectal cancer.Cell 1996, 87:159-170.

Kim, J.H. et al. Pellino-1, an adaptor protein of interleukin-1receptor/toll-like receptor signaling, is sumoylated by Ubc9. Mol. Cells31, 85?89 (2011).

Kanneganti TD, Lamkanfi M, Nunez G. Intracellular NOD-like receptorsin host defense and disease. Immunity 2007;27:549?559.

Jie Hui Li, Nancy C. Kirkiles-Smith, Jennifer M. McNiff, Jordan S. Pober.TRAIL Induces Apoptosis and Inflammatory. J Immunol 2003; 171:1526-1533.

Jiang, Z. et al. Pellino 1 is required for interleukin-1 (IL-1)-mediatedsignaling through its interaction with the IL-1 receptor-associated kinase4 (IRAK4)-IRAK-tumor necrosis factor receptor-associated factor 664(TRAF6) complex. J. Biol. Chem. 278, 10952?10956 (2003).

Jiang, X. & Chen, Z. J. The role of ubiquitylation in immune defence andpathogen evasion. Nature Rev. Immunol. 12, 35?48 (2012).

Jensen, L.E. & Whitehead, A.S. Pellino3, a novel member of the Pellinoprotein family, promotes activation of c-Jun and Elk-1 and may act as ascaffolding protein. J. Immunol. 171, 1500?1506 (2003).

Jensen, L.E. & Whitehead, A.S. Pellino2 activates the mitogen activatedprotein kinase pathway. FEBS Lett. 545, 199?202 (2003).

Janssen, E. M., Droin, N. M., Lemmens, E. E., Pinkoski, M. J., Bensinger,S. J., Ehst, B. D., et al. (2005).CD4+T-cell help controls CD8+ T-cellmemory via TRAIL-mediated activation-induced cell death. Nature,434(7029), 88?93.

Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2leucinerich repeat variants with susceptibility to Crohn ?s disease. Nature.2001; 411:599?603.

Hayakawa, Y., Screpanti, V., Yagita, H., Grandien, A., Ljunggren, H. G.,Smyth, M. J., et al. (2004).NKcell TRAIL eliminates immature dendriticcells in vivo and limits dendritic cell vaccination efficacy. J. Immunol.,172(1), 123?129.

Grosshans, J., Schnorrer, F. & Nusslein-Volhard, C. Oligomerisation ofTube and Pelle leads to nuclear localisation of dorsal. Mech. Dev. 81,127?138 (1999).

Garber K: First results for agents targeting cancer-related inflammation. JNatl Cancer Inst 2009, 101:1110-1112.

Fukata M, Shang L, Santaolalla R, Sotolongo J, Pastorini C, et al. (2011)Constitutive activation of epithelial TLR4 augments inflammatoryresponses to mucosal injury and drives colitis-associated tumorigenesis.Inflamm Bowel Dis 17: 1464?1473.

Fukata M, Chen A, Vamadevan AS, Cohen J, Breglio K, et al. (2007)Toll-like receptor-4 promotes the development of colitis-associatedcolorectal tumors. Gastroenterology 133: 1869?1881.

Franchi L, Warner N, Viani K, et al. Function of Nod-like receptors inmicrobial recognition and host defense. Immunol Rev 2009;227:106?128.

Fox NL, Humphreys R, Luster TA, Klein J, Gallant G. Tumor NecrosisFactor-related apoptosis-inducing ligand (TRAIL) Receptor-1 andReceptor-2 agonists for cancer therapy. Expert Opin Biol Ther 2010;10:1?18.

Finn OJ: Cancer immunology. N Engl J Med 2008, 358:2704-2715.

Falschlehner C, Schaefer U, Walczak H. Following TRAIL ?s path in theimmune system. Immunology 2009; 127:145?54.

Eyking A, Ey B, Runzi M, Roig AI, Reis H, et al. (2011) Toll-likeReceptor 4 Variant D299G Induces Features of Neoplastic Progression inCaco-2 Intestinal Cells and Is Associated With Advanced Human ColonCancer. Gastroenterology.

Emery JG, McDonnell P, Burke MB et al. Osteoprotegerin is a receptorfor the cytotoxic ligand TRAIL. J Biol Chem 1998; 273:14363?7.

Earl TM, Nicoud IB, Pierce JM, Wright JP, Majoras NE, et al. (2009)Silencing of TLR4 decreases liver tumor burden in a murine model ofcolorectal metastasis and hepatic steatosis. Ann Surg Oncol 16: 1043?1050.

Dupaul-Chicoine, J., G. Yeretssian, K. Doiron, K. S. Bergstrom, C. R.McIntire, P. M. LeBlanc, C. Meunier, C. Turbide, P. Gros, N. Beauchemin,et al. 2010. Control of intestinal homeostasis, colitis, and colitisassociatedcolorectal cancer by the inflammatory caspases. Immunity 32:367?378.

Di Bartolo BA, Chan J, Bennett MR, Cartland S, Bao S, Tuch BE,Kavurma MM. TNFrelated apoptosis-inducing ligand (TRAIL) protectsagainst diabetes and atherosclerosis in Apoe/mice. Diabetologia 2011;54:3157?67.

Cretney E, Takeda K, Yagita H, Glaccum M, Peschon JJ, Smyth MJ.97Increased susceptibility to tumor initiation and metastasis in TNF-relatedapoptosis-inducing ligand-deficient mice. J Immunol 2002; 168:1356?61.

Cretney E, McQualter JL, Kayagaki N, Yagita H, Bernard CC, Grewal IS,Ashkenazi A, Smyth MJ. TNF-related apoptosis-inducing ligand(TRAIL)/Apo2L suppresses experimental autoimmune encephalomyelitisin mice. Immunol Cell Biol 2005; 83:511?19.

Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A: Cancer-relatedinflammation, the seventh hallmark of cancer: links to genetic instability.Carcinogenesis 2009, 30:1073-1081.

Chen, G., Shaw, M. H., Kim, Y. G. & Nunez, G. NOD-like receptors: rolein innate immunity and inflammatory disease. Annu. Rev. Pathol. 4, 365?398 (2009).62

Chang, M. et al. The ubiquitin ligase Peli1 negatively regulates T cellactivation and prevents autoimmunity. Nat. Immunol. 12, 1002?1009(2011).

Cammarota R, Bertolini V, Pennesi G, Bucci EO, Gottardi O, et al. (2010)The tumor microenvironment of colorectal cancer: stromal TLR-4expression as a potential prognostic marker. J Transl Med 8: 112.

Butler, M.P., Hanly, J.A. & Moynagh, P.N. Pellino3 is a novel upstreamregulator of p38 MAPK and activates CREB in a p38-dependent manner.J. Biol. Chem. 280, 27759?27768 (2005).

Butler, M.P., Hanly, J.A. & Moynagh, P.N. Kinase-active interleukin-1receptorassociated kinases promote polyubiquitination and degradation ofthe Pellino family: direct evidence for PELLINO proteins beingubiquitin-protein isopeptide ligases. J. Biol. Chem. 282, 29729?29737(2007).

Bresalier RS: Early detection of and screening for colorectal neoplasia.Gut Liver 2009, 3:69-80.

Brenner H, Hoffmeister M, Haug U: Should colorectal cancer screeningstart at the same age in European countries? Contributions fromdescriptive epidemiology. Br J Cancer 2008, 99:532-535.

Ashkenazi A, Herbst RS. To kill a tumor cell: the potential ofproapoptotic receptor agonists. J Clin Invest 2008; 118:1979?90.

Adhikari, A., Xu, M. & Chen, Z.J. Ubiquitin-mediated activation ofTAK1 and IKK. Oncogene 26, 3214?3226 (2007).

Aderem, A., 2003. Phagocytosis and the inflammatory response. J. Infect.Dis. 187, S340?S345.